Element Capital Management LLC Buys New Position in Johnson & Johnson $JNJ

Element Capital Management LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, HoldingsChannel reports. The firm purchased 12,389 shares of the company’s stock, valued at approximately $2,564,000. Johnson & Johnson accounts for about 1.2% of Element Capital Management LLC’s portfolio, making the stock its 19th biggest holding.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Evolve Private Wealth LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $8,462,000. Capitolis Liquid Global Markets LLC boosted its holdings in shares of Johnson & Johnson by 478.7% during the 4th quarter. Capitolis Liquid Global Markets LLC now owns 219,911 shares of the company’s stock worth $45,511,000 after buying an additional 181,911 shares in the last quarter. Catalio Capital Management LP acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $25,008,000. Claro Advisors Inc. increased its stake in shares of Johnson & Johnson by 1.6% in the 4th quarter. Claro Advisors Inc. now owns 21,619 shares of the company’s stock valued at $4,474,000 after acquiring an additional 340 shares in the last quarter. Finally, Clay Northam Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $217,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $233.44 on Thursday. The company has a market capitalization of $561.95 billion, a price-to-earnings ratio of 26.99, a PEG ratio of 2.30 and a beta of 0.26. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a 50 day moving average of $231.07 and a 200 day moving average of $227.93.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a report on Wednesday, April 15th. Daiwa Securities Group upped their price target on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Bank of America raised their price objective on Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Johnson Rice raised Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Finally, Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.